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Abstract
The purpose of this investigation was to determine whether acute doxorubicin intoxication causes a preferential
 .  .accumulation of 8-hydroxydeoxyguanosine 8OHdG adducts to mitochondrial DNA mtDNA as opposed to nuclear DNA
 .  .nDNA , particularly in cardiac tissue. Adult male rats received a single i.p. bolus of doxorubicin 15 mgrkg and were
killed 1–14 days later. Acute intoxication with doxorubicin caused a 2-fold greater increase in 8OHdG adducts to mtDNA
compared to nDNA, the concentration of adducts to both nDNA and mtDNA being 20%–40% greater for heart as opposed
 .to liver. For both tissues, the relative abundance of adducts was highest at the earliest time-point examined 24 h and
decreased to control values by 2 weeks. The temporal dilution of 8OHdG adducts was not the result of cell hyperplasia and
was only partially due to amplification of the mitochondrial genome, most probably via an increase in DNA copy number
rather than a stimulation of mitochondrial biogenesis. q 1997 Elsevier Science B.V.
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 .8-Hydroxydeoxyguanosine 8OHdG adducts of
both nuclear and mitochondrial DNA nDNA and
.mtDNA, respectively accumulate over the life span
w xof an individual 1–5 . The extent of accumulation
varies among tissues, being most pronounced in mi-
totically fixed, aerobically active tissues such as brain
w xand cardiac and skeletal muscle 6 . The origin of
these adducts is believed to be the reaction of free
radical species of oxygen, specifically the hydroxyl
free radical, with DNA to cause the preferential
w xhydroxylation of deoxyguanosine at C 7 . In mito-8
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chondria, which are deficient in DNA repair enzymes
w x8–11 , the 8OHdG adducts accumulate with repeated
oxidative insult. Contrast this with nuclei which have
a proficient DNA repair capacity.
The accumulation of 8OHdG adducts of mtDNA is
dependent not only on intrinsic metabolic rates, but it
is also influenced by extrinsic factors such as envi-
ronmental exposure histories. For example, exposure
of animal cells in culture to polyaromatic hydrocar-
bons, nitrosamines or azo dyes results in a 40–500-
fold increase in concentration of mtDNA adducts
w xcompared to nDNA adducts 12–15 . A similar pref-
erential accumulation of mtDNA adducts occurs fol-
lowing in vivo exposure to carbon tetrachloride, ni-
w xtrosamines or aflatoxin 10,15–18 . The ratio of
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mtDNArnDNA adducts ranges between 2 and 50,
depending on the toxic agent, the tissue, and the time
elapsed since exposure.
The accumulation of mtDNA adducts and the asso-
ciated interference with genomic template activity
may explain many of the metabolic and bioenergetic
deficits associated with chemical intoxication. For
example, acute intoxication of rats with perfluorooc-
tane sulfonamide results in a preferential accumula-
tion of 8OHdG adducts of mtDNA in liver but not
w xkidney tissue 19 . This may reflect tissue-specific
sites of metabolic activation and correlates with the
fact that perfluorooctane sulfonamide causes peroxi-
some proliferation and hepatocellular carcinomas but
w xis not suspected of being nephrotoxic 20 . Accord-
ingly, analysis of 8OHdG mtDNA adducts may pro-
vide a reliable biomarker for tissue-specific oxidative
injury in response to oxidant exposure in vivo.
One such agent that is of considerable clinical
importance is the anthracycline antibiotic, doxoru-
 w.bicin Adriamycin , which is a potent, broad-spec-
trum antineoplastic agent used for treating a number
of both solid tumors and leukemias. However, the
clinical utility is limited by the incidence of a life-
threatening cardiomyopathy in patients receiving a
2 w xcumulative dose exceeding 550 mgrm 21 . The
mechanism of cardiotoxicity involves redox cycling
of the drug on the endoplasmic reticulum andror
mitochondrial membranes to liberate highly reactive
w xfree radical species of oxygen 22 . In cardiac tissue,
in which mitochondria comprise up to 50% of the
total cell volume, the principal intracellular site of
redox cycling is on complex I of the respiratory chain
w x23,24 . We recently reported an 8-fold increase in
concentration of 8OHdG adducts of nDNA in rat
liver following acute intoxication with doxorubicin
w x w x25 . Cho et al. 26 demonstrated an organ-specific
accumulation of 8OHdG adducts to nDNA in kidney,
as opposed to liver, following acute intoxication with
doxorubicin. This is consistent with the drug causing
kidney tumors but not liver tumors. The purpose of
the present investigation was to determine if there is
a preferential accumulation of 8OHdG adducts of
mtDNA compared to nDNA following acute doxoru-
bicin exposure and whether there is any selectivity
for heart tissue.
 .Male Sprague–Dawley rats 200–250 g were pur-
 .chased from Harlan Sprague–Dawley Madison, WI
and housed in an AAALAC-accredited, climate-con-
 .trolled 218C, 14r10 h light cycle animal care facil-
ity. The animals were allowed to acclimate for at
least 5 days with free access to food Purina Rodent
.Diet No. 5001 and water. Five rats each were in-
jected i.p. with a single bolus of either 15 mgrkg
 wdoxorubicin Adriamycin , Adria Laboratories,
.  .Columbus, OH or an equivalent volume 1 mlrkg
of 0.9% NaCl. The rats were later killed by decapita-
tion and both the heart and liver quickly excised to
 . cold 48C MSEM 225 mM mannitolr75 mM su-
.croser1 mM EGTAr10 mM MOPS, pH 7.4 .
The isolation of both heart and liver mitochondria
w xwas precisely as described previously 27,28 . To 1.5
g of heart tissue was added 2.5 ml of protease Type
 .VIII Sigma Chemical, St. Louis, MO at 5 urml in
MSEM. The tissue was homogenized gently for 30 s
 .glass-Teflon Potter–Elvehjem then immediately di-
 .luted with 26.25 ml fresh, protease-free MSEM 48C
and the homogenization continued for an additional
60 s. The homogenate was centrifuged at 8000=g
for 10 min at 48C. The pellet was resuspended in 30
ml fresh MSEM and stored on ice.
 .The liver was homogenized in 20 vols. mlrg
protease-free MSEM. Nuclei were separated from
mitochondria by centrifuging both the liver ho-
mogenate and the resuspended pellet of the heart
homogenate at 1500=g for 10 min at 48C. The
supernatants containing the mitochondria were sepa-
rated and stored on ice. The pellets were washed by
 .resuspending in fresh MSEM 20 vols. . This was
diluted 6-fold with additional MSEM then re-centri-
fuged at 1500=g for 10 min at 48C. The washed
nuclear pellet was resuspended in 4 vols. of TSE 100
.mM Trisr160 mM sucroser10 mM EDTA, pH 7.5
and stored on ice.
Mitochondria were recovered from the original
1500=g supernatants by centrifuging for 15 min at
12 000=g. The mitochondrial pellets were resus-
pended in 20 vols. fresh MSEM and re-centrifuged at
12 000=g for 15 min. The final mitochondrial pel-
lets were resuspended in 2 vols. mlrg original tis-
.  .sue of 100 mM Trisr160 mM sucrose pH 7.5 to
which was added 2.5 mgrml DNase I Sigma, Type
.IV . Mitochondrial cytochrome oxidase and citrate
synthase activities were measured prior to digesting
with DNAse. The remaining sample was digested for
30 min at 378C and the reaction stopped by adding
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EDTA to a final concentration of 25 mM. The mito-
chondria were recovered by centrifugation 11 000=
.g for 15 min and re-suspended in 2 vols. of fresh
TSE.
Both the nuclear and mitochondrial fractions were
then solubilized in 2.7% SDS and digested with
 .proteinase K 400 mgrml, Sigma for 3 h at 378C.
DNA was extracted with 2 vols. of phenolrchloro-
 .formriso-amyl alcohol 25:24:1 . The phases were
separated by centrifugation at 1000=g for 5 min.
The aqueous phase was recovered by aspiration and
re-extracted. Nucleic acids were precipitated by
adding 0.1 vols. of 3 M potassium acetate and 2 vols.
cold ethanol, then left at y208C overnight. The DNA
precipitate was collected by centrifugation 20 000=
.g for 2 h at 48C and resuspended in 400 ml 100 mM
 .Trisr10 mM EDTA pH 7.5 . Contaminating RNA
was removed by digesting for 2 h at 378C with
 .RNases A and T ca. 2 and 125 units, respectively .1
The digested DNA was precipitated in potassium
acetaterethanol overnight at y208C. The DNA pre-
cipitate was collected by centrifugation 20 min at
.maximum speed in a microfuge and washed once
with cold 70% ethanol.
The washed DNA was then hydrolyzed by sequen-
tial digestion with DNase I, nuclease P1, and alkaline
phosphatase and the final deoxynucleotides stored
w xfrozen at pH 7.8 until analyzed 29 . The concentra-
tion of 8OHdG adducts to each of the corresponding
DNA fractions was quantified by LCrESIrMSrMS
liquid chromatographyrelectrospray ionizationr
.tandem mass spectrometry as previously described
w x25 . 8OHdG standards were synthesized by oxidizing
 .commercial deoxyguanosine dG; Sigma Chemical
in a Fenton reaction medium consisting of 1 mM
hydroquinone, 5 mM H O , 0.1 mM FeCl , and 0.52 2 3
w xmM EDTA 30 . The instrument was calibrated with
these synthetic standards on the basis of the MSrMS
peak area response. The data are expressed as the
relative abundance of 8OHdG adducts per 100 000
dG nucleosides.
Male rats injected with saline gained approxi-
mately 5.3 grday, averaged over 14 days. Doxoru-
bicin-intoxicated rats, however, failed to gain weight
 .data not shown . Although the increase in liver mass
was similar for the two groups, there was no increase
in heart weight for animals treated acutely with dox-
 .orubicin data not shown . In control animals, heart
weight increased from an average of 1.1 g on the day
of injection to 1.55 g at 2 weeks.
The concentration of 8OHdG adducts to both
nDNA and mtDNA of liver and heart following acute
intoxication with doxorubicin is illustrated in Fig. 1.
 5In all cases, the relative abundance adducts per 10
.dG nucleosides was maximum at the earliest time
 .examined 24 h . The concentration of adducts de-
creased exponentially thereafter, reaching control val-
ues by 1–2 weeks following the single injection of
doxorubicin. The relative abundance of 8OHdG
adducts to nDNA and mtDNA in control rats was
between 1 and 4 per 105 dG for both liver and heart
 .data not shown . For both tissues at all time-points,
the concentration of adducts to mtDNA was substan-
tially higher than that for nDNA. For example, 24 h
after an acute dose of doxorubicin, the ratio of mtDNA
to nDNA adducts was 1.9 for liver and 2.2 for heart.
Furthermore, the concentration of 8OHdG adducts
was, without exception, higher in heart compared to
liver. This was true for both nDNA and mtDNA
adducts.
The time-dependent decline in the relative abun-
dance of nDNA adducts was not due to dilution with
native genomic DNA, as would occur with cell pro-
Fig. 1. Temporal changes in the relative abundance of 8OHdG
adducts to both mtDNA and nDNA from heart and liver of
doxorubicin intoxicated rats. Rats were injected i.p. with a single
dose of 15 mgrkg doxorubicin. Mitochondria and nuclei were
isolated by differential centrifugation and the DNA isolated and
analyzed by LCrESIrMSrMS for 8OHdG adducts. The concen-
tration of the adducts is expressed in terms of unmodified dG
nucleosides. Each point represents the mean of duplicate experi-
mental samples. The standard deviation between samples was
less than the diameter of the corresponding symbol.
( )C.M. Palmeira et al.rBiochimica et Biophysica Acta 1321 1997 101–106104
liferation. The evidence is that the peak area response
was very consistent among samples of nDNA Fig.
.2 . Since a constant fraction of the total isolated DNA
was analyzed each time, the peak area response
provides a quantitative measure of total sample dG
nucleosides. As illustrated in Fig. 2, peak area re-
sponse for liver or heart nDNA from either control or
treated animals did not change appreciably over time.
In contrast, the peak area response of dG in both
heart and liver mtDNA increased approximately 50%
and 30%, respectively, within 3–7 days of the acute
 .injection of doxorubicin Fig. 2 . This measure of
total mtDNA remained elevated 2 weeks following
doxorubicin intoxication.
The preferential accumulation of mtDNA adducts
 .Fig. 2. Concentration of total unmodified deoxyguanosine dG
 .  .bases in both liver upper panel and heart lower panel from
 .  .control Ct and doxorubicin intoxicated Tx rats. dG concentra-
tion is expressed as the MS response factor on the basis of
sample volume injected, which was always 4% of the total
sample recovered from 1.5 g of tissue. Each point represents the
mean of duplicate experimental samples. The standard deviation
was less than the diameter of the respective symbols.
in vivo has been demonstrated following acute intoxi-
cation of rats or hamsters with various genotoxic
w xagents 10,15–18,31 . There are a number of factors
that may account for this. It may be that the hy-
drophobic xenobiotics preferentially partition to the
w xlipid enriched mitochondrial membranes 12,14,15 .
The close physical association of mtDNA to the inner
mitochondrial membrane, which harbors the
metabolic enzymes required for drug activation, fa-
vors the formation of mtDNA adducts. The absence
from mitochondria of histone and non-histone pro-
teins, which sheath the nDNA by providing a diffu-
sional barrier to reactive genotoxic intermediates,
w xalso favors the formation of mtDNA adducts 32–34 .
Finally, mitochondria lack the proficient excision-
and recombination-DNA repair mechanisms charac-
w xteristic of the nuclear genome 8–11 . Therefore,
once formed there is a higher probability for the
retention of unrepaired DNA adducts in mitochon-
dria.
It is interesting to note the greater accumulation of
adducts in cardiac tissue compared to liver, despite
the fact that the rate of metabolic bioactivation of
doxorubicin by cardiac microsomes is only 10–15%
w xthat of hepatic microsomes 35 . We are left to con-
clude either that the rate of metabolic activation of
doxorubicin by microsomal enzyme systems is not a
limiting factor or that comparisons of rates of drug
metabolism measured in vitro do not accurately re-
flect that which occur in vivo. Alternatively, it is well
established that doxorubicin undergoes rapid univa-
lent reduction by NADH:ubiquinone oxidoreductase
of the mitochondrial electron transport chain to initi-
ate a futile redox cycle, liberating oxygen free radi-
cals in the immediate vicinity of the mitochondrial
w xgenome 23,24 . Since mitochondria constitute up to
50% of the cell volume in myocytes, it could be that
the principal site of metabolic activation and free
radical generation in heart is the mitochondria, not
the endoplasmic reticulum.
Regardless, the preferential accumulation of
mtDNA adducts, especially in heart tissue, following
acute intoxication with doxorubicin may account for
many of the bioenergetic deficits associated with the
cardiotoxicity observed in vivo. Such effects include
the depletion of ATP, inhibition of both NADH- and
succinate-cytochrome c reductase activities of the
electron transport chain, and inhibition of respiratory
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w xcontrol by ADP 36–38 . These bioenergetic deficits
are observed in mitochondria isolated from heart, but
w xnot liver, of intoxicated rats 39 . Since the mitochon-
drial genome provides exclusive encoding for 13 of
the more than 80 proteins of the respiratory chain,
mutations to the mtDNA, if unrepaired or not replen-
ished, would result in an irreversible bioenergetic
deficit. This is consistent with the cumulative and
irreversible decline in cardiac performance observed
clinically with doxorubicin.
The temporal dilution of 8OHdG adducts within
both the mitochondrial and nuclear DNA of heart and
liver suggests either rapid repair or amplification of
the respective genomes. The time-dependent decline
in relative abundance of nDNA adducts was expected
because of the well characterized and efficient ge-
nomic repair mechanisms localized within the nucle-
oplasm. However, because of the virtual absence of
w xmitochondrial DNA repair mechanisms 8–11 , we
did not expect to observe the resolution of the mtDNA
adducts. One could suggest that cell hyperplasia might
explain the dilution of mtDNA adducts in liver, but
not heart. However, the fact that we did not observe
an increase in total nuclear dG nucleotides i.e., DNA
.content indicates that the degree of toxic tissue
injury, and thus the dose, was insufficient to elicit a
mitogenic response. What was observed, though, was
amplification of both the cardiac and hepatic mito-
chondrial genomes following acute intoxication with
doxorubicin. Whether this reflects an increase in
mitochondrial number or an increase in gene copy
per individual mitochondrion remains unknown. The
fact that we did not observe a treatment-related in-
crease in either cytochrome oxidase or citrate syn-
thase activities over this 2-week period data not
.shown favors an increase in mtDNA copy number as
opposed to a stimulation of mitochondrial biogenesis.
Although the time-course for genomic amplification
correlates with the dilution of mtDNA adducts, it
does not quantitatively account for the 5–6-fold dilu-
tion of 8OHdG adducts observed over the first week
post-treatment.
Amplification of the mitochondrial genome occurs
in response to a number of metabolically stressful
situations such as exercise, hypoxia or hypertension
and is essential to accommodating the exaggerated
metabolic demands. Despite the importance of this
phenomenon, very little is known regarding the pre-
cise signal that regulates mitochondrial biogenesis.
Whatever the signaling pathway is, it apparently is
responsive to the metabolic challenge associated with
acute doxorubicin intoxication.
In conclusion, we suggest that the tissue and mito-
chondrial specific accumulation of 8OHdG adducts
may be important in the phenotypic manifestation of
bioenergetic deficits accompanying the cardiomyopa-
thy associated with doxorubicin administration in
vivo. Prevention of this adduct formation, potentia-
tion of further genomic amplification, or development
of therapies for circumventing the mitochondrial bio-
energetic deficits may provide important opportuni-
ties for improving the clinical success of this impor-
tant therapeutic regimen for treating a host of human
cancers.
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